Sodium-Glucose Cotransporter-2 Inhibitor Use and Risk of Lower-Extremity Amputation: Evolving Questions, Evolving Answers

BACKGROUND: Canagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), was associated with an approximately two-fold increase in amputation risk in a recent cardiovascular outcome trial. Observational studies in real-world data have yielded mixed or inconclusive results. METHODS: We conduct...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Diabetes Obes Metab
Main Authors: Yang, Jeff Y., Wang, Tiansheng, Pate, Virginia, Gower, Emily W., Crowley, Matthew J., Buse, John B., Stürmer, Til
Formato: Artigo
Idioma:Inglês
Publicado: 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6459697/
https://ncbi.nlm.nih.gov/pubmed/30697897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13647
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares